CTI's Bianco retires

CTI BioPharma Corp. (NASDAQ:CTIC; Milan:CTIC) said President and CEO James Bianco has retired from the company. Director Richard Love will serve as interim president and CEO.

In a statement, Bianco said that with pacritinib ( BAX 2201) at its current development stage, the time is right "for me to retire and pursue other passions in my life." The company has completed two Phase III trials of the myelofibrosis candidate. It is under a full clinical hold by FDA. ...